Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.
about
Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosisHDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applicationsAnti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cellsHDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disordersIdentification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in miceMacrophages in the pathogenesis of atherosclerosisTemplated spherical high density lipoprotein nanoparticles.Lack of P2Y13 in mice fed a high cholesterol diet results in decreased hepatic cholesterol content, biliary lipid secretion and reverse cholesterol transport.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.Carotid artery stiffness, high-density lipoprotein cholesterol and inflammation in men with pre-hypertension.RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotectionAnti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewCholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein.High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport.Management of low levels of high-density lipoprotein-cholesterol.Omega 3 fatty acids promote macrophage reverse cholesterol transport in hamster fed high fat diet.Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance.Biological properties of apolipoprotein a-I mimetic peptides.Anticipatory role of high density lipoprotein and endothelial dysfunction: an overviewLow serum high density lipoprotein cholesterol concentration is an independent predictor for enhanced inflammation and endothelial activation.Alginic acid cell entrapment: a novel method for measuring in vivo macrophage cholesterol homeostasis.HDL cholesterol efflux capacity and incident cardiovascular events.Anion exchange HPLC isolation of high-density lipoprotein (HDL) and on-line estimation of proinflammatory HDLRestoration of renal function does not correct impairment of uremic HDL propertiesEffects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions.P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivoReactive Secondary Sequence Oxidative Pathology Polymer Model and Antioxidant Tests.Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.Future therapeutic directions in reverse cholesterol transport.Novel HDL-directed pharmacotherapeutic strategies.Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.Serum amyloid A in uremic HDL promotes inflammationSerum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES StudyHigh-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation
P2860
Q24603711-B449C510-AF94-45C9-84AF-4039535F350FQ26779667-B3F3B5F2-ABB6-4E96-BBF1-884E3B43C098Q27012536-D9579037-155C-45C2-BBD1-902C9F24E4C6Q27691344-222DD14D-2404-4464-ABDF-2284F4EC61F9Q28588894-D7EC2FD6-7C63-4726-B78A-8ADEC8755A94Q29617765-378A9B91-6DD6-4334-8FFB-65F58875DAC1Q33398727-F53AC94D-82E8-47D9-8186-496678C89C60Q33642949-71D5FDFD-BD03-427D-8E63-3381C6FB630FQ33993233-D852DCBB-F995-45A3-8577-3C7DAE120DE3Q34035255-AE8EF059-D4D4-4820-AEC4-84C431D02B0EQ34038348-D29D8FC3-B389-4E3E-BFC6-20F5ACF91F87Q34215871-7FC5E103-9E94-4BDA-AE71-7C0ADA59741CQ34238630-73175B61-6520-4351-94A4-DDECE99A6D25Q34243501-42957C50-BA4A-494F-B856-25247679A5A4Q34314185-0A740E08-494C-4142-BA1A-B4A5E331F46FQ34334697-7E6FC8A2-5288-4B7E-A36D-94078BA41C5EQ34428756-0B29BD3B-19D1-4B8C-BBB5-5DE7CF3C483EQ34509936-7B6C767D-F5F2-407E-8FD9-FB082DEAC1AEQ34684069-C7809B7F-14E9-4B6D-AE70-D2EB1D93C514Q34905815-D95E4FE3-6102-4BC3-8956-E25366005DA8Q34927488-416D3577-E239-4597-B3C7-CFD6E5CF73DAQ34950045-725FA4BE-1DE6-4BC8-861F-8E7FB1A8D880Q35007253-4CCF19C2-3AED-4B72-82E3-B20A0BB79996Q35014329-487788C6-9ED1-4E81-BDA3-0A0677EC0C22Q35021594-AD0CD7F0-C8E1-489E-A8EC-320DCF4E619AQ35114897-2B30D1A2-C029-4AA4-9377-86204CA1B179Q35124223-628D5126-3D57-4D76-99E5-06757D594952Q35129072-871F3396-AFFE-4543-89DD-2BFD0FF9B94BQ35149530-A861F761-49CE-468C-B84D-E42956BD799CQ35158162-5340B61C-86C2-4AAE-8456-3D9603A16F32Q35504522-FD3C017E-8E33-4C0D-B38B-6DD6CE8EBB83Q35683158-2FE383DC-2B40-4217-B46F-D7E8D7651BCBQ35860010-A5D5009B-0A21-4D88-959B-ECCD00FCB461Q35860020-45E787F8-876A-419A-975A-0AAB3E8D3BB1Q35895453-DA0E93E6-4A54-4EAD-B10F-20B1745D2094Q35917487-65C5909F-4466-48F3-B1CB-30016CE550B3Q36110734-779DCDE9-DD71-452D-9AAA-E86C51A8D0DDQ36139932-99A25BBA-4240-452F-AE48-27E64BFA27ABQ36152978-ADD40959-86EC-4C4A-85DB-47EC85C9421CQ36237663-5098068D-D8DF-4D1D-9AD8-5CBE52B57C2B
P2860
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@ast
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@en
type
label
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@ast
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@en
prefLabel
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@ast
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@en
P2093
P2860
P1476
Beyond high-density lipoprotei ...... novel therapeutic approaches.
@en
P2093
Daniel J Rader
Emil M deGoma
Rolando L deGoma
P2860
P304
P356
10.1016/J.JACC.2008.03.016
P407
P577
2008-06-01T00:00:00Z